Mustang Bio: Rises on positive early data from blood cancer therapy study

Mustang Bio

11/06/2021 12:28

** Drug developer's shares  MBIO.O  rise 6.3% to $4.05
premarket
    ** Co updates interim data from its ongoing early stage
clinical trial investigating safety and efficacy of MB-106 for
high-risk B-cell non-Hodgkin lymphomas and chronic lymphocytic
leukemia - both types of blood cancers  urn:newsml:reuters.com:*:nGNX4gF61b
    ** Says data for MB-106, a CAR T cell therapy, shows
favorable safety profile and compelling clinical activity
    ** Data shows 93% overall response rate and 67% complete
response rate in patients - MBIO
    ** As of last close, MBIO stock up about 1% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com;))